Abstract
Tumor infiltrating lymphocytes (TIL) entering the tumor microenvironment (TME) encounter many suppressive factors resulting in a spectrum of possible differentiation paths, many with overlapping characteristics. This differentiation spectrum includes T cell anergy, unresponsiveness, quiescence, tolerance, dysfunction/suppression, and exhaustion, each with many subtypes. Immune checkpoint blockade (ICB) cancer drug therapies have focused on reinvigorating exhausted T cells (TEX) and dysfunctional T cells (herein referred to as TEX). Many factors have been attributed to as causative to this exhausted state including sustained surface expression of multiple co-inhibitory receptors, altered transcription factor expression, epigenetic rewiring, and dysregulated metabolism. Antigen persistence is necessary for driving TEX maintenance in both the chronic viral infection setting and cancer. In addition to persistent antigen exposure, TILs within the TME encounter numerous tumor-mediated immunosuppressive metabolic by-products, suppressive cytokines, hypoxia, and cellular debris which converge to suppress T cell function and uniquely alter its transcription factor profile. These suppressed or dysfunctional T cells are incapable of mounting an optimal anti-tumor response in part due to lack of fitness in competing for glucose and oxygen. This chapter describes two different potency assays: (a) first we describe optimization of a core recall antigen-based in vitro potency assay for screening of immunopotentiating drug candidates; (b) the second assay bundles the core assay with further addition of immunosuppressive agents derived from the TME making a customizable T cell exhaustion-like assay. Our recall antigen assay is being used as a tool for function-based screening of ICB drug candidates. In this assay healthy human Peripheral Blood Mononuclear Cells (PBMCs) are stimulated with peptide(s) and grown in culture for 1 week. Day 4 supernatants are functionally assayed by ELISA for IFN-γ secretion, and cells are assayed on day 7 by flow cytometry for CD8+ or CD4+ T cell expansion by using a single or cocktail of pMHC tetramers. We have shown that in roughly 30% of donor PBMCs, ICB drugs such as pembrolizumab are able to boost both IFN-γ secretion and antigen-specific recall. One potential explanation for this effect is that the observed increase in T cell co-inhibitory receptor expression and presumed co-inhibitory receptor downstream signaling is ameliorated with ICB drugs releasing these T cells from the repressive effects of these co-inhibitory receptors. We have further enhanced our recall assay to more closely resemble the TME by including metabolites and other suppressive agents at concentrations not normally encountered by T cells in a healthy environment. We show one example of this whereby addition of adenosine to the culture results in suppression of antigen-specific T cell expansion without affecting cell viability. Further, we screened several drug candidates on their ability to counteract the negative effects of adenosine and found that one of the drugs was indeed able to restore antigen-specific T cell expansion. Hence, this TME-based recall antigen assay allows for dissection of the effects of TME-based factors on donor-specific T cell response as well as drug candidate screening.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486–499
McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 37:457–495
Hashimoto M et al (2018) CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med 69:301–318
Shin H et al (2007) Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 204(4):941–949
Schietinger A et al (2016) Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45(2):389–401
Yi JS, Cox MA, Zajac AJ (2010) T-cell exhaustion: characteristics, causes and conversion. Immunology 129(4):474–481
Crawford A et al (2014) Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40(2):289–302
Thommen DS, Schumacher TN (2018) T cell dysfunction in cancer. Cancer Cell 33(4):547–562
Chang CH et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241
Eil R et al (2016) Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537(7621):539–543
Vodnala SK et al (2019) T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science 363(6434):pii:eaau0135
Ohta A, Metabolic Immune A (2016) Checkpoint: adenosine in tumor microenvironment. Front Immunol 7:109
Anderson KG, Stromnes IM, Greenberg PD (2017) Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31(3):311–325
Revenfeld ALS et al (2017) Induction of a regulatory phenotype in CD3+ CD4+ HLA-DR+ T cells after allogeneic mixed lymphocyte culture; indications of both contact-dependent and -independent activation. Int J Mol Sci 8:7
Ghosh S et al (2019) TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol Cancer Ther 18(3):632–641
Wang C et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2(9):846–856
Grenga I et al (2016) A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol 5(5):e83
Li Y et al (2018) Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer 6(1):31
European Medicines Agency (2016) Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer. European Medicines Agency, London
Wang Y et al (2017) How an alloreactive T-cell receptor achieves peptide and MHC specificity. Proc Natl Acad Sci U S A 114(24):E4792–E4801
Hundrieser J et al (2019) Role of human and porcine MHC DRB1 alleles in determining the intensity of individual human anti-pig T-cell responses. Xenotransplantation 26:e12523
Haley Laken KM, Murtaza A, de Silva Correia J, McNeeley P, Zhang J, Vancutsem P, Wilcoxen K, Jenkins D (2016) Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich
Lamphear JG, Stevens KR, Rich RR (1998) Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule. J Immunol 160(2):615–623
Gjetting T et al (2019) Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. MAbs 11(4):666–680
Krakauer T (2017) FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights. Immunotargets Ther 6:17–29
Jones RB et al (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205(12):2763–2779
Wang W et al (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21(9):1065–1077
Lichtenegger FS et al (2018) Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol 9:385
Filippis C et al (2017) Nivolumab enhances in vitro effector functions of PD-1(+) T-lymphocytes and leishmania-infected human myeloid cells in a host cell-dependent manner. Front Immunol 8:1880
Li Pira G et al (2008) Evaluation of antigen-specific T-cell responses with a miniaturized and automated method. Clin Vaccine Immunol 15(12):1811–1818
Duffy D (2018) Standardized Immunomonitoring: separating the signals from the noise. Trends Biotechnol 36(11):1107–1115
Bucks CM et al (2009) Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol 182(11):6697–6708
Eikawa S, Mizukami S, Udono H (2014) Monitoring multifunctionality of immune-exhausted CD8 T cells in cancer patients. Methods Mol Biol 1142:11–17
Balkhi MY et al (2018) YY1 upregulates checkpoint receptors and downregulates type I cytokines in exhausted, chronically stimulated human T cells. iScience 2:105–122
Hefti FF (2008) Requirements for a lead compound to become a clinical candidate. BMC Neurosci 9(Suppl 3):S7
Smith SG et al (2017) Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials. PLoS One 12(10):e0184391
Acknowledgements
All assays and data were generated at JSR Life Sciences and MBL International. M.C.T. trained as an intern at JSR Life Sciences when she contributed to some studies.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kleiman, E. et al. (2020). Induction and Potential Reversal of a T Cell Exhaustion-Like State: In Vitro Potency Assay for Functional Screening of Immune Checkpoint Drug Candidates. In: Tan, SL. (eds) Immuno-Oncology. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0171-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0171-6_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0170-9
Online ISBN: 978-1-0716-0171-6
eBook Packages: Springer Protocols